12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Emergent BioSolutions preclinical data

In a mouse xenograft model of prostate cancer, 3 and 30 µg doses of ES414 led to complete inhibition of tumor growth and a 100%...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >